Vol. 2 No. 7 (2022)
Reimbursement Reviews

Fostamatinib (Tavalisse)

Published July 12, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses fostamatinib (Tavalisse), 100 mg or 150 mg tablet, oral.
  • Indication (Health Canada indication): for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to other treatments.